Scalper1 News
Big pharmas Merck (MRK) and Bristol-Myers Squibb (BMY) released new data on their hot new immunotherapy cancer drugs Friday afternoon, but the results sent their stocks in opposite directions. Bristol’s stock dropped 6.6% after the release of two late-breaker abstracts on studies of its drug Opdivo, a PD-1 inhibitor, for the American Society of Clinical Oncology (ASCO) meeting that opened Friday and will continue through the weekend. The study Scalper1 News
Scalper1 News